E. Kaplan

发表

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

E. Winer, S. Edge, C. Shapiro, 2010, Journal of the National Cancer Institute.

Factor V l eiden Mutation and t hromboembolism r isk in Women r eceiving Adjuvant t amoxifen for Breast c ancer

E. Winer, S. Edge, C. Shapiro, 2010 .

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

M. Morris, J. Moul, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.

A. Armstrong, E. Small, O. Sartor, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

The short-term impact of tailored mammography decision-making interventions.

G P Samsa, B. Rimer, G. Samsa, 2001, Patient education and counseling.

Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial

N. Petrelli, J. Baron, R. Sandler, 2001, Cancer.

Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia

E. Paskett, R. Hohl, J. Atkins, 2004, Cancer.

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

P. Kantoff, M. Kattan, E. Small, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.

E. Small, J. Picus, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

E. Small, B. Rini, J. Picus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

A. Armstrong, E. Small, C. Sternberg, 2013, Journal of the National Cancer Institute.

Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.

E. Basch, A. Bennett, T. Atkinson, 2012, Pain medicine.

Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).

M. Morris, E. Small, S. Halabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample

B. Rimer, C. McBride, C. Skinner, 1999 .

Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.

J. Bono, A. Armstrong, E. Small, 2012 .

Effects of a mammography decision-making intervention at 12 and 24 months.

Susan Halabi, Barbara K Rimer, Isaac M Lipkus, 2002, American journal of preventive medicine.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

E. Small, J. Picus, N. Vogelzang, 2012, Cancer.

Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583.

P. Kantoff, E. Small, C. Ryan, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic M odel f or P redicting S urvival i n M en W ith Hormone-Refracto ry M etastatic P rostate C ancer

P. Kantoff, M. Kattan, E. Small, 2003 .

Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma

John D. Roberts, N. Vogelzang, J. Atkins, 2002, Cancer.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

E. Winer, S. Edge, C. Shapiro, 2010, Journal of the National Cancer Institute.

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

E. Small, S. Halabi, W. Kelly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.